



Living Cell Technologies Limited

CAN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Appendix 4C Quarterly Cash Flow Report 30 September 2013

29 October 2013 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced its quarterly cash flow report for the quarter ended 30 September 2013. The Appendix 4C is attached. The company ended the quarter with a cash balance of \$4,761,000 compared to \$4,504,000 last quarter.

Dr Andrea Grant, Managing Director, said "LCT's net cash flow continues to be very well controlled even with the company running two human clinical trial programs, DIABECCELL for type 1 diabetes and NTCELL for Parkinson's disease. This is because the costs associated with both clinical programs are being recouped, through the joint venture Diatranz Otsuka Limited and the co-development partnership with Otsuka Pharmaceutical Factory respectively."

Net operating cash flow in the quarter was \$157,000 compared to (\$398,000) last quarter. Receipts from customers were \$2,869,000 (last quarter \$2,178,000). These included \$393,000 of services fees from the joint venture company to be refunded in January. Operating payments were \$2,845,000 compared to \$2,640,000 last quarter. 87% of these payments are recovered as receipts from customers through LCT's co-development and joint venture agreements.

During the September quarter, LCT achieved a significant milestone in safely transplanting the first patient in the Phase I clinical trial of NTCELL for Parkinson's. Under the co-development agreement with OPF, LCT may receive a \$2m milestone payment provided the data safety monitoring board gives permission for the remaining three patients in the Phase I trial to be implanted when it meets early in December of this year.

– Ends –

For further information: www.lctglobal.com

<p>At the company: Dr Andrea Grant Managing Director Tel: +64 9 270 7941 Mobile: +64 21 078 5421 agrant@lctglobal.com</p> <p>John Cowan Head of Finance & Administration Tel: +64 9 276 2690 Mobile: +64 21 469000</p>	<p>Media enquires – NZ: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz</p> <p>Media enquiries – Australia & World Shevaun Cooper Buchan Consulting Tel: +61 3 9866 4722</p>
---	---

jcowan@lctglobal.com

Mobile: +61 421 760 775
scooper@buchanwe.com.au

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL[®], for the treatment of Type 1 diabetes and NTCELL[®], which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease.

Through an innovative joint venture, Diatrans Otsuka Limited (DOL) with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECELL and the Phase I clinical trials of NTCELL in Parkinson's disease. LCT retains a 50% share of future profits from DIABECELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the DOL partnership.

LCT's unique, proprietary technology, IMMUPEL[™], allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.